Minerva cardiology and angiology最新文献_第9页

Spontaneous coronary artery dissection: review, case report and analysis of COVID-19-related cases. 自发性冠状动脉夹层：COVID-19 相关病例的回顾、病例报告和分析。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-06-01 Epub Date: 2023-02-27 DOI: 10.23736/S2724-5683.22.06195-6

Joseph Cosma, Alessandro Russo, Valentina Ferradini, Cecilia Gobbi, Vincenzo Mallia, Andrea Zuffi, Cédric Joret, Salvatore Sacca, Ruggiero Mango

{"title":"Spontaneous coronary artery dissection: review, case report and analysis of COVID-19-related cases.","authors":"Joseph Cosma, Alessandro Russo, Valentina Ferradini, Cecilia Gobbi, Vincenzo Mallia, Andrea Zuffi, Cédric Joret, Salvatore Sacca, Ruggiero Mango","doi":"10.23736/S2724-5683.22.06195-6","DOIUrl":"10.23736/S2724-5683.22.06195-6","url":null,"abstract":"Spontaneous coronary artery dissection (SCAD) accounts for 1-4% of all acute coronary syndromes (ACS). Since the first description in 1931, our understanding of the disease has evolved; however, its pathophysiology and management are still a matter of debate. SCAD typically occurs in a middle-aged woman with no or few traditional cardiovascular risk factors. Two hypotheses have been proposed to explain the pathophysiology depending on the primary event: an intimal tear in the \"inside-out\" hypothesis and a spontaneous hemorrhage from the vasa vasorum in the \"outside-in\" hypothesis. Etiology appears to be multifactorial: different predisposing and precipitating factors have been identified. Coronary angiography is the gold standard for the diagnosis of SCAD. Current recommendations on the treatment of SCAD patients are based on expert opinions: a conservative strategy is preferred in hemodynamically stable SCAD patients, while urgent revascularization should be considered in hemodynamically unstable patients. Eleven cases of SCAD in COVID-19 patients have already been described: although the exact pathophysiological mechanism remains unclear, COVID-19-related SCAD is considered a combination of significant systemic inflammatory response and localized vascular inflammation. We present a literature review of SCAD, and we report an unpublished case of SCAD in a COVID-19 patient.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"251-265"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10837983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term mortality rate of patients with ST-elevation myocardial infarction and cardiogenic shock treated with primary PCI. 经皮冠状动脉介入治疗ST段抬高型心肌梗死和心源性休克患者的长期死亡率。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-06-01 Epub Date: 2023-09-21 DOI: 10.23736/S2724-5683.23.06408-6

Marco Loffi, Silvia Frattini, Marta Mazzotta, Chiara Bernelli, Gian B Danzi

引用次数: 0

Chronic systemic glucocorticoid therapy is associated with increased risk of major vascular complications and cardiac tamponade after transcatheter aortic valve implantation: a systematic review and meta-analysis. 慢性全身性糖皮质激素治疗与经导管主动脉瓣植入术后主要血管并发症和心脏压塞风险增加相关：一项系统综述和荟萃分析。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-06-01 Epub Date: 2023-10-12 DOI: 10.23736/S2724-5683.23.06347-0

Juan G Chiabrando, Marco Lombardi, Ignacio M Seropian, Juan M Valle Raleigh, Rocco Vergallo, Miguel Larribau, Carla R Agatiello, Carlo Trani, Francesco Burzotta

{"title":"Chronic systemic glucocorticoid therapy is associated with increased risk of major vascular complications and cardiac tamponade after transcatheter aortic valve implantation: a systematic review and meta-analysis.","authors":"Juan G Chiabrando, Marco Lombardi, Ignacio M Seropian, Juan M Valle Raleigh, Rocco Vergallo, Miguel Larribau, Carla R Agatiello, Carlo Trani, Francesco Burzotta","doi":"10.23736/S2724-5683.23.06347-0","DOIUrl":"10.23736/S2724-5683.23.06347-0","url":null,"abstract":"Introduction: TAVI-related complications, such as conduction disturbances, vascular complications or death may be related to increased inflammatory response. The aim of this study was to elucidate the efficacy and safety of the systemic glucocorticoid therapy regarding the adverse events after TAVI deployment.Evidence acquisition: We conducted a systemic search of PubMed, a reference list of relevant articles, and Medline. The main efficacy outcomes of interest were all-cause death, cardiac and non-cardiac death, permanent pacemaker implantation (PPM), new left bundle branch block (LBBB), stroke, and myocardial infarction (MI). Safety endpoints were major vascular complications, major bleeding events, and cardiac tamponade.Evidence synthesis: A total of 7 studies including data from 3439 patients with a median follow-up was 30 days. Systemic glucocorticoid compared to the control group were associated with an increased risk of non-cardiac death (Relative Risk [RR] 5.90 95%CI [2.95; 11.80], P<0.001) major vascular complications (RR 1.78, 95%CI [1.22 - 2.61], P=0.003) and cardiac tamponade (RR 3.42, 95%CI [1.69 - 6.92], P<0.001). However, there were no differences in all-cause death, cardiac death, new LBBB, stroke, MI, or major bleeding events (all P values >0.05).Conclusions: Glucocorticoid therapy before the TAVI procedure was associated with an increase in non-cardiac death, major vascular events and cardiac tamponade. There were no differences in the risk of all-cause death, cardiac death, PPM or LBBB, stroke, or MI.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"284-291"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41205186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial fibrillation and ischemic heart disease: (un)solved therapeutic dilemma? 心房颤动和缺血性心脏病：（未）解决治疗难题？

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-06-01 Epub Date: 2023-10-23 DOI: 10.23736/S2724-5683.23.06275-0

Valeria Gritti, Simona Pierini, Marco Ferlini, Silvia Mauri, Lucia Barbieri, Battistina Castiglioni, Corrado Lettieri, Luca Mircoli, Andrea Mortara, Daniele Nassiacos, Luigi Oltrona Visconti, Anita Paggi, Francesco Soriano, Carlo Sponzilli, Alberto Corsini

{"title":"Atrial fibrillation and ischemic heart disease: (un)solved therapeutic dilemma?","authors":"Valeria Gritti, Simona Pierini, Marco Ferlini, Silvia Mauri, Lucia Barbieri, Battistina Castiglioni, Corrado Lettieri, Luca Mircoli, Andrea Mortara, Daniele Nassiacos, Luigi Oltrona Visconti, Anita Paggi, Francesco Soriano, Carlo Sponzilli, Alberto Corsini","doi":"10.23736/S2724-5683.23.06275-0","DOIUrl":"10.23736/S2724-5683.23.06275-0","url":null,"abstract":"Concomitant presence of atrial fibrillation and coronary artery disease requiring percutaneous coronary intervention is a frequent occurrence. The choice of optimal antithrombotic therapy, in this context, is still challenging. To offer the best protection both in terms of stroke and stent thrombosis, triple therapy with oral anticoagulation and dual antiplatelet therapy would be required. Several drug combinations have been tested in recent years, including direct oral anticoagulants, with the aim of balancing ischemic and bleeding risk. Both pharmacokinetic aspects of the molecules and patient's characteristics should be analyzed in choosing oral anticoagulation. Then, as suggested by guidelines, triple therapy should start with a seven-day duration and the aim to prolong to thirty days in high thrombotic risk patients. Dual therapy should follow to reach twelve months after coronary intervention. Even not fully discussed by the guidelines, in order to balance ischemic and bleeding risk it should also be considered: 1) integrated assessment of coronary artery disease and procedural complexity of coronary intervention; 2) appropriateness to maintain the anticoagulant drug dosage indicated in technical data sheet; the lack of data on the suspension of antiplatelet drugs one year after percutaneous intervention; 3) the possibility of combination therapy with ticagrelor; and 4) the need to treat the occurrence of paroxysmal atrial fibrillation during acute coronary syndrome. With data provided clinician should pursue a therapy as personalized as possible, both in terms of drug choice and treatment duration, in order to balance ischemic and bleeding risk.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"225-236"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49691424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Upfront scoring balloon predilatation in treatment of de-novo lesions with drug-coated balloon angioplasty. 药物涂层球囊血管成形术治疗新发病变的球囊预扩张术。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-06-01 Epub Date: 2023-10-23 DOI: 10.23736/S2724-5683.23.06451-7

Rajinikanth Rajagopal

引用次数: 0

Sodium-glucose cotransporter-2 inhibitors: a swinging pendulum in the treatment of acute myocardial infarction. 钠-葡萄糖共转运体-2 抑制剂：治疗急性心肌梗死的钟摆。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-06-01 Epub Date: 2023-05-10 DOI: 10.23736/S2724-5683.22.06200-7

Buena Aziri, Edin Begic, Bojan Stanetic, Zorica Mladenovic, Tamara Kovacevic-Preradovic

{"title":"Sodium-glucose cotransporter-2 inhibitors: a swinging pendulum in the treatment of acute myocardial infarction.","authors":"Buena Aziri, Edin Begic, Bojan Stanetic, Zorica Mladenovic, Tamara Kovacevic-Preradovic","doi":"10.23736/S2724-5683.22.06200-7","DOIUrl":"10.23736/S2724-5683.22.06200-7","url":null,"abstract":"Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are integral in treating patients with heart failure, regardless of the existence of diabetes mellitus. In light of their benefits on the heart muscle, the question of their effect on acute coronary syndrome is raised, and a hypothesis as to whether they can be implemented in its treatment is proposed. The aim of the article was to indicate the potential of using SGLT2 inhibitors in the treatment of myocardial infarction (MI).Evidence acquisition: A PubMed search for articles published between October 2017 and May 2022 was conducted using the following keywords: \"SGLT2 inhibitors,\" \"Acute Coronary Syndrome,\" \"Treatment,\" \"Prognosis.\" Reference lists of identified articles were searched for further articles.Evidence synthesis: Reports from clinical trials and animal studies thus far investigating mechanistic pathways of SGLT2 inhibitors' effect in relation to acute myocardial infarction were interplayed to extract relevant findings and analyze the safety of this therapy in acute coronary syndrome (ACS) patients.Conclusions: SGLT2 inhibitors indicate beneficial effects in acute cardiovascular incident by various mechanisms, and early initiation of therapy may improve outcomes for AMI survivors.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"237-250"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9444205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hidden vulnerable plaques make the most noise: optical coherence tomography in patients with ST segment elevation myocardial infarction and multivessel disease. 隐藏的脆弱斑块噪音最大：ST 段抬高型心肌梗死和多血管疾病患者的光学相干断层扫描。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-06-01 Epub Date: 2024-01-31 DOI: 10.23736/S2724-5683.23.06508-0

Francesca M DI Muro, Carlo DI Mario, Alessio Mattesini

引用次数: 0

Recognition and reward in peer review: The ReviewerCredits vision. 同行评审中的认可与奖励：ReviewerCredits 愿景。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-06-01 Epub Date: 2024-01-31 DOI: 10.23736/S2724-5683.23.06487-6

Sven Fund, Gareth Dyke

引用次数: 0

Association between Dietary Inflammatory Index (DII) and sarcopenia in ischemic heart disease: an 1999-2004 NHANES study of 1088 US individuals. 缺血性心脏病患者的膳食炎症指数（DII）与肌肉疏松症之间的关系：1999-2004 年对 1088 名美国人进行的 NHANES 研究。

IF 1.6 4区医学

Minerva cardiology and angiology Pub Date : 2024-05-27 DOI: 10.23736/S2724-5683.24.06496-2

Xiao-Yun Zheng, Yi Chen, Yan Gao, Mo Zhou, Wen-Zhuo Guan

{"title":"Association between Dietary Inflammatory Index (DII) and sarcopenia in ischemic heart disease: an 1999-2004 NHANES study of 1088 US individuals.","authors":"Xiao-Yun Zheng, Yi Chen, Yan Gao, Mo Zhou, Wen-Zhuo Guan","doi":"10.23736/S2724-5683.24.06496-2","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06496-2","url":null,"abstract":"Background: The aim of this study was to investigate the relationship between DII and sarcopenia in individuals with ischemic heart disease (IHD).Methods: This was a retrospective study utilizing data of the National Health and Nutrition Examination Survey (NHANES) from 1999-2004. Adults aged ≥50 years diagnosed with IHD, having complete 24-hour dietary recall data, and dual energy X-ray absorptiometry (DEXA)-measured muscle mass were eligible for inclusion. Association between DII and sarcopenia, defined by reduced appendicular skeletal muscle mass, was determined by the logistic regression analyses.Results: Data of 1088 individuals were analyzed, with the mean age of 68.1±0.5 years. Significantly higher DII was observed in the sarcopenic group compared to the non-sarcopenic group (0.24 vs. -0.17, P=0.020). After adjusting for relevant confounders in the multivariable analysis, each unit increase in DII was significantly associated with higher odds of sarcopenia (adjusted odd ratio [aOR]=1.07, 95% confidence interval: 1.00-1.14, P value = 0.040). In stratified analyses, among patients with a Body Mass Index (BMI) ≥30 kg/m2, both DII tertile 2 and tertile 3 were significantly associated with greater odds of sarcopenia (tertile 2 vs. tertile 1: aOR=2.85, 95% CI: 1.56-5.23, P=0.001; tertile 3 vs. tertile 1: aOR=3.11, 95% CI: 1.53-6.31, P=0.002), whereas no significant associations was observed among patients with a BMI<30 kg/m2.Conclusions: This study has established a significant independent association between a higher DII and an increased risk of sarcopenia in US adults with IHD regardless of type of IHD. BMI appears as a moderating factor in this association.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Future of factor XI inhibitors in cardiovascular practice. XI 因子抑制剂在心血管领域的应用前景。

IF 1.6 4区医学

Minerva cardiology and angiology Pub Date : 2024-05-27 DOI: 10.23736/S2724-5683.23.06474-8

Antonio Greco, Nicola Ammirabile, Davide Landolina, Antonino Imbesi, Carmelo Raffo, Davide Capodanno

{"title":"Future of factor XI inhibitors in cardiovascular practice.","authors":"Antonio Greco, Nicola Ammirabile, Davide Landolina, Antonino Imbesi, Carmelo Raffo, Davide Capodanno","doi":"10.23736/S2724-5683.23.06474-8","DOIUrl":"https://doi.org/10.23736/S2724-5683.23.06474-8","url":null,"abstract":"Anticoagulation is indicated for treatment and prevention of arterial and venous thrombosis. Targeting different steps of the coagulation process, currently available anticoagulants entail an increased risk of bleeding, which detrimentally impacts on prognosis and hinders the administration of an effective antithrombotic regimen. Factor XI (FXI) inhibition has emerged as a strategy to uncouple prevention of thrombosis from bleeding. Indeed, while FXI is crucial for the amplification phase in pathological thrombosis, it is ancillary in physiological hemostasis. A comprehensive search in several scientific databases has been performed to identify relevant studies in the field. In addition, ongoing trials have been searched for in proper datasets to provide an updated and comprehensive assessment of the current state of investigations on FXI inhibition. Many compounds have been tested to inhibit FXI at different stages (i.e., synthesis, activation, or interactions with target molecules and coagulation factors). These include antisense oligonucleotides, monoclonal antibodies, small molecules, natural peptides and aptamers. In phase 2 studies, FXI inhibitors reduced thrombotic complications without any corresponding increase in bleeding. FXI inhibitors were noninferior and potentially superior to low-molecular-weight heparin in orthopedic surgery and reduced bleeding compared to apixaban in patients with atrial fibrillation. FXI inhibition is also under testing in other conditions, including end-stage renal disease, cancer, or noncardioembolic stroke. FXI inhibition represents a promising and rapidly emerging approach for a number of clinical indications. This article reviews the rationale, evidence, pharmacology, and future applications of FXI inhibition.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0